Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRMD-001 (Deferiprone) for Contrast-Induced AKI
NCT01146925Phase 2Completed
- Sponsor
- CorMedix Inc.
- Start
- Jun 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deferiprone in contrast-associated acute kidney injury (CA-AKI) (2 arms), sponsored by CorMedix Inc. Primary endpoint: Biomarker evidence of Acute Kidney injury at 8 days. Started Jun 2010; status: completed.
02
Drugs
deferiprone
03
Conditions
contrast-associated acute kidney injury (CA-AKI)
Beyond the preview
Go deeper on NCT01146925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146925.